Intech Investment Management LLC Invests $94,000 in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Intech Investment Management LLC bought a new position in Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the third quarter, Holdings Channel.com reports. The firm bought 56,904 shares of the biopharmaceutical company’s stock, valued at approximately $94,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Capital Advisors Wealth Management LLC boosted its position in Esperion Therapeutics by 22.9% during the 2nd quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock worth $59,000 after buying an additional 5,000 shares during the period. Boomfish Wealth Group LLC raised its holdings in Esperion Therapeutics by 17.1% during the 3rd quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 5,102 shares during the last quarter. Summit Financial LLC lifted its position in shares of Esperion Therapeutics by 26.4% in the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 6,823 shares during the period. National Bank of Canada FI raised its stake in Esperion Therapeutics by 115.9% during the second quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 10,225 shares during the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Esperion Therapeutics by 45.3% in the second quarter. SG Americas Securities LLC now owns 37,414 shares of the biopharmaceutical company’s stock valued at $83,000 after buying an additional 11,658 shares during the period. 47.39% of the stock is owned by institutional investors.

Esperion Therapeutics Price Performance

ESPR stock opened at $3.48 on Monday. The stock has a market cap of $685.68 million, a PE ratio of -5.44 and a beta of 1.01. The firm has a 50 day simple moving average of $2.29 and a two-hundred day simple moving average of $2.20. Esperion Therapeutics, Inc. has a one year low of $1.35 and a one year high of $3.81.

Analysts Set New Price Targets

Several equities analysts have issued reports on ESPR shares. StockNews.com lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Needham & Company LLC decreased their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Tuesday, December 3rd.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.